A Phase II, Multicentre, Randomised, Placebo-controlled, Doublemasked Trial of RP101 Ophthalmic Formulation Versus Vehicle in Post-menopausal Women With Moderate to Severe Dry Eye Syndrome
Latest Information Update: 23 Mar 2021
Price :
$35 *
At a glance
- Drugs RP 101-Redwood Pharma (Primary)
- Indications Dry eyes
- Focus Proof of concept; Therapeutic Use
- Sponsors Redwood Pharma
- 22 Mar 2021 According to a Redwood Pharma media release, data from this trial will be presented in a poster presentation at the upcoming virtual annual meeting of the US-based research organization Association for Research in Vision and Ophthalmology
- 12 Mar 2021 Results assessing safety, efficacy and the effective dose of topical estradiol ophthalmic formulation (RP101) in postmenopausal women with moderate-to-severe dry eye disease published in the Advances in Therapy.
- 29 Dec 2020 Topline results published in the Redwood Pharma Media Release